Clinuvel Pharmaceuticals Limited (CLVLY)
OTCMKTS · Delayed Price · Currency is USD
7.30
+0.25 (3.51%)
Sep 5, 2025, 12:11 PM EDT
Clinuvel Pharmaceuticals Revenue
In the fiscal year ending June 30, 2025, Clinuvel Pharmaceuticals had annual revenue of 95.02M AUD with 7.76% growth. Clinuvel Pharmaceuticals had revenue of 59.37M in the half year ending June 30, 2025, with 21.27% growth.
Revenue
95.02M AUD
Revenue Growth
+7.76%
P/S Ratio
5.96
Revenue / Employee
5.94M AUD
Employees
16
Market Cap
371.02M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 95.02M | 6.84M | 7.76% |
Jun 30, 2024 | 88.18M | 9.86M | 12.59% |
Jun 30, 2023 | 78.32M | 12.60M | 19.17% |
Jun 30, 2022 | 65.72M | 17.40M | 36.02% |
Jun 30, 2021 | 48.32M | 15.75M | 48.37% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Veradigm | 588.02M |
Elite Pharmaceuticals | 105.45M |
Tian'an Technology Group | 2.12M |
Glass House Brands | 221.55M |
Northwest Biotherapeutics | 1.09M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.17M |
Longduoduo Company | 4.99M |
Clinuvel Pharmaceuticals News
- 8 days ago - Clinuvel Pharmaceuticals Limited 2025 Q4 - Results - Earnings Call Presentation - Seeking Alpha
- 8 days ago - Clinuvel Pharmaceuticals Limited (CLVLY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 8 days ago - Clinuvel Pharmaceuticals reports FY results - Seeking Alpha
- 14 days ago - CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist - GlobeNewsWire
- 4 months ago - CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105 - GlobeNewsWire
- 6 months ago - Half Year 2025 Clinuvel Pharmaceuticals Ltd Earnings Call Transcript - GuruFocus
- 6 months ago - Clinuvel Introduces Groundbreaking Vitiligo Program at the World's Biggest Dermatology Meeting, AAD 2025 - GlobeNewsWire
- 6 months ago - Clinuvel Pharmaceuticals Limited (CLVLY) Q2 2025 Earnings Call Transcript - Seeking Alpha